Syncona

What is Syncona ?

Syncona is a UK-based venture capital investment subsidiary of Wellcome Trust that engages in the founding, building, and funding of global leaders in life science. With its foundation in London in 2012, Syncona operates with a unique model that combines the capital growth dynamics of a life science company with the liquidity and diversification of a fund.

The firm is characterized by a hands-on approach to invest in transformative healthcare technologies and businesses, particularly in the fields of IT & TMT, BioTech, IoT & Wearables, Life Science, and Oncology. Syncona invests with a long-term perspective, aiming to build strong, standalone businesses that can produce innovative treatments for patients.

Each investment aligns with a clear patient impact framework, ensuring both societal and shareholder value. Syncona's venture capital activities involve seed investments with both minimum and maximum amounts set at £117,550,000.

The investment process focuses on creating a diversified portfolio of 20-25 leading healthcare companies through close partnerships with scientists and entrepreneurs, fostering environments that support growth and success. This structured and disciplined approach includes stages from pre-clinical, clinical, to late-stage companies, emphasizing value maximization throughout the investment cycle.

Furthermore, Syncona is committed to sustainability and responsible investment, including efforts to inspire and empower their people, conduct ethical business practices, achieve net zero targets, and make significant charitable donations, particularly in healthcare.

Syncona's portfolio contains a range of businesses at varying stages of development, such as Autolus Therapeutics, Quell Therapeutics, and Purespring Therapeutics, reflecting the fund’s belief in unlocking potential from innovative science to transform patient lives. The fund has also shown dedication to contributing positively to society beyond financial means, as demonstrated by the activities of The Syncona Foundation.